| CAS NO: | 501698-03-9 |
| 包装 | 价格(元) |
| 250mg | 电议 |
| 500mg | 电议 |
| Cas No. | 501698-03-9 |
| Canonical SMILES | O=C(NC1=CC=CC(C)=C1)NC2=CC=C(C3=CSC4=NC=NC(N)=C43)C=C2 |
| 分子式 | C20H17N5OS |
| 分子量 | 375.45 |
| 溶解度 | DMSO : 62.5 mg/mL (166.47 mM);Water :< 0.1 mg/mL (insoluble) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | GDP366, a dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells. GDP366 potently and selectively inhibits the expression of both survivin and Op18. GDP366 decreass both the mRNA and protein levels of survivin and Op18. This inhibitory effect is not dependent on the status of p53 and p21 although GDP366 potently increases p53 and p21 levels. GDP366 significantly inhibits the growth of tumor cells in vitro and in vivo (nude mouse model) without rapid induction of apoptosis. GDP366 induces polyploidy in multiple types of cancer cell lines. GDP366 increases chromosomal instability, and induces cellular senescence by inhibiting telomerase activity[1]. [1]. Shi X, et al. GDP366, a novel small molecule dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells. Cancer Biol Ther. 2010 Apr 15;9(8):640-50. |
m.cnreagent.com